Leverage Shares 2X Long FIX Daily ETF (BATS:FIXX) Sees Large Drop in Short Interest

Leverage Shares 2X Long FIX Daily ETF (BATS:FIXX) was the recipient of a large decline in short interest in September. As of September 30th, there was short interest totaling 2,984 shares, a decline of 39.7% from the September 15th total of 4,949 shares. Based on an average daily volume of 2,478 shares, the days-to-cover ratio is currently 1.2 days.

Leverage Shares 2X Long FIX Daily ETF Stock Down 6.5%

Shares of FIXX opened at $10.29 on Friday. Leverage Shares 2X Long FIX Daily ETF has a twelve month low of $9.14 and a twelve month high of $15.92.

Insiders Place Their Bets

In related news, insider Shelia M. Violette sold 2,798 shares of Leverage Shares 2X Long FIX Daily ETF stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total value of $46,334.88. Following the completion of the transaction, the insider owned 127,771 shares in the company, valued at $2,115,887.76. The trade was a 2.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Lee Kalowski sold 3,972 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $16.56, for a total transaction of $65,776.32. Following the transaction, the chief financial officer owned 138,471 shares of the company’s stock, valued at $2,293,079.76. This trade represents a 2.79% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 22,054 shares of company stock worth $320,397 in the last quarter.

Homology Medicines, Inc was a clinical-stage biotechnology company focused on developing genetic medicines for patients with rare diseases. The company sought to use its proprietary human-derived adeno-associated virus vectors, known as AAVHSCs, to deliver gene therapies in vivo and address the underlying causes of inherited disorders.

Its development programs included HMI-103, an investigational gene therapy for phenylketonuria, as well as earlier programs targeting other rare diseases.